| Lung Cancer |
1 |
1 |
| Biologic Therapy |
0 |
0.85 |
| Chemotherapy |
0 |
0.67 |
| Adjuvant Chemotherapy |
0 |
0.98 |
| Neoadjuvant Therapy |
0 |
0.97 |
| Combination Chemotherapy |
0 |
0.49 |
| Non-Small Cell Lung Cancer |
0 |
0.99 |
| Immunotherapy |
0 |
0.17 |
| Tumor |
0 |
0.17 |
| Biomarker |
0 |
0.12 |
| Platinum |
0 |
0.12 |
| Surgery |
0 |
0.12 |
| Small Cell Lung Cancer |
0 |
0.11 |
| Cancer |
0 |
0.1 |
| Genomic Medicine |
0 |
0.08 |
| Lung |
0 |
0.07 |
| Resection |
0 |
0.07 |
| Board Certification |
0 |
0.05 |
| Healthcare and Medical Technology |
0 |
0.03 |
| Anaplastic Lymphoma Kinase |
0 |
0.02 |
| Clinical Research |
0 |
0.02 |
| Epidermal Growth Factor Receptor |
0 |
0.02 |
| Europe |
0 |
0.02 |
| Hospital |
0 |
0.02 |
| Medical Oncology |
0 |
0.02 |
| Postoperative |
0 |
0.02 |
| Preoperative |
0 |
0.02 |